FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112873670> ?p ?o ?g. }

• W3112873670 endingPage "S185" @default.
• W3112873670 startingPage "S184" @default.
• W3112873670 abstract "Context Identifying targetable and driver mutation and fusions in myeloid neoplasms through NGS platform. Objective The aim of this study was to optimize and validate Oncomine Myeloid Research Assay (comprising of 40 DNA target genes, 29 driver genes, and a broad fusion panel) for establishing assay sensitivity, specificity, and precision using Ion torrent PGM and implementation into clinics. Patients or other participants Archived DNA samples (n=17) with known mutations in (FLT3-ITD, CEBPA, NPM1, PTPN11, cMPL1, IDH1/2, TET, EZH2, U2AF1, SETBP1, ASLX1, TP53) and RNA samples (n=11) with FISH/RT-PCR-confirmed fusions (NUP 214, RUNX1, PML RARA BCR 1, PML RARA BCR 3, MLLT3, B14A3, B19A2) were retrieved as positive controls and negative controls for the validation. The sequences were analyzed using variant calling software (Ion Reporter Annotate variants version 5.4, 5.6, and 5.10) caller to identify variants relevant to the clinical indication. After thorough optimization and validation, this panel was used for prospective analysis in patients with suspected myeloid disorders. [AML (n=36), MDS (n=12), MPN (n=9)] AUL (n=1), Cytopenia/anaemia under evaluation (n=8) and CMML (n=3)]. Intervention FLT3-ITD by fragment analysis was performed in all cases after validation. Main outcome measures After implementation of NGS platform in myeloid neoplasms FLT3 and TET2 genes were the most common pathogenic variant in DNA sequencing and KMT2A rearrangement on RNA sequencing. Results In the four validation runs (318 chip - 4 DNA/RNA) comprising 28 known variants, all mutations/rearrangements were concordant except two cases (FLT3-ITD > 200bp and SETBP1, G870S 3.2%). For the prospective myeloid disorders (n=69), mutations were observed in 31 genes, maximum cases having FLT3 (n=8) and TET2 (n=8). The other frequently mutated genes were SRSF2 (n=7), NRAS (n=6), RUNX1 (n=6), ASXL1 (n=6), CEBPA (n=5), U2AF1 (n=4), SH2B3 (n=4), BCOR (n=4). All FLT3-ITD-positive and -negative cases were confirmed by Fragment Length Analysis. In eleven cases, fusions were detected; KMT2A (n=4), BCR-ABL (n=3), PML-RARA (bcr3) (n=1), and RUNX1T1 (n=2) and ETV6-ABL fusions Conclusions We demonstrate the validation and implementation of a combined targeted DNA and RNA sequencing for routine clinical use in myeloid malignancies. Identifying targetable and driver mutation and fusions in myeloid neoplasms through NGS platform. The aim of this study was to optimize and validate Oncomine Myeloid Research Assay (comprising of 40 DNA target genes, 29 driver genes, and a broad fusion panel) for establishing assay sensitivity, specificity, and precision using Ion torrent PGM and implementation into clinics. Archived DNA samples (n=17) with known mutations in (FLT3-ITD, CEBPA, NPM1, PTPN11, cMPL1, IDH1/2, TET, EZH2, U2AF1, SETBP1, ASLX1, TP53) and RNA samples (n=11) with FISH/RT-PCR-confirmed fusions (NUP 214, RUNX1, PML RARA BCR 1, PML RARA BCR 3, MLLT3, B14A3, B19A2) were retrieved as positive controls and negative controls for the validation. The sequences were analyzed using variant calling software (Ion Reporter Annotate variants version 5.4, 5.6, and 5.10) caller to identify variants relevant to the clinical indication. After thorough optimization and validation, this panel was used for prospective analysis in patients with suspected myeloid disorders. [AML (n=36), MDS (n=12), MPN (n=9)] AUL (n=1), Cytopenia/anaemia under evaluation (n=8) and CMML (n=3)]. FLT3-ITD by fragment analysis was performed in all cases after validation. After implementation of NGS platform in myeloid neoplasms FLT3 and TET2 genes were the most common pathogenic variant in DNA sequencing and KMT2A rearrangement on RNA sequencing. In the four validation runs (318 chip - 4 DNA/RNA) comprising 28 known variants, all mutations/rearrangements were concordant except two cases (FLT3-ITD > 200bp and SETBP1, G870S 3.2%). For the prospective myeloid disorders (n=69), mutations were observed in 31 genes, maximum cases having FLT3 (n=8) and TET2 (n=8). The other frequently mutated genes were SRSF2 (n=7), NRAS (n=6), RUNX1 (n=6), ASXL1 (n=6), CEBPA (n=5), U2AF1 (n=4), SH2B3 (n=4), BCOR (n=4). All FLT3-ITD-positive and -negative cases were confirmed by Fragment Length Analysis. In eleven cases, fusions were detected; KMT2A (n=4), BCR-ABL (n=3), PML-RARA (bcr3) (n=1), and RUNX1T1 (n=2) and ETV6-ABL fusions We demonstrate the validation and implementation of a combined targeted DNA and RNA sequencing for routine clinical use in myeloid malignancies." @default.
• W3112873670 created "2020-12-21" @default.
• W3112873670 creator A5000555731 @default.
• W3112873670 creator A5020985923 @default.
• W3112873670 creator A5037861726 @default.
• W3112873670 creator A5056422504 @default.
• W3112873670 creator A5067147178 @default.
• W3112873670 creator A5068225545 @default.
• W3112873670 creator A5070631722 @default.
• W3112873670 creator A5074194089 @default.
• W3112873670 creator A5091640477 @default.
• W3112873670 date "2020-09-01" @default.
• W3112873670 modified "2023-09-26" @default.
• W3112873670 title "AML-142: Implementation of Combined DNA and RNA Sequencing in Myeloid Neoplasms" @default.
• W3112873670 doi "https://doi.org/10.1016/s2152-2650(20)30721-7" @default.
• W3112873670 hasPublicationYear "2020" @default.
• W3112873670 type Work @default.
• W3112873670 sameAs 3112873670 @default.
• W3112873670 citedByCount "0" @default.
• W3112873670 crossrefType "journal-article" @default.
• W3112873670 hasAuthorship W3112873670A5000555731 @default.
• W3112873670 hasAuthorship W3112873670A5020985923 @default.
• W3112873670 hasAuthorship W3112873670A5037861726 @default.
• W3112873670 hasAuthorship W3112873670A5056422504 @default.
• W3112873670 hasAuthorship W3112873670A5067147178 @default.
• W3112873670 hasAuthorship W3112873670A5068225545 @default.
• W3112873670 hasAuthorship W3112873670A5070631722 @default.
• W3112873670 hasAuthorship W3112873670A5074194089 @default.
• W3112873670 hasAuthorship W3112873670A5091640477 @default.
• W3112873670 hasConcept C104317684 @default.
• W3112873670 hasConcept C127848430 @default.
• W3112873670 hasConcept C151730666 @default.
• W3112873670 hasConcept C2483381 @default.
• W3112873670 hasConcept C2778729363 @default.
• W3112873670 hasConcept C2779282312 @default.
• W3112873670 hasConcept C2779343474 @default.
• W3112873670 hasConcept C2779694297 @default.
• W3112873670 hasConcept C30481170 @default.
• W3112873670 hasConcept C45091340 @default.
• W3112873670 hasConcept C501734568 @default.
• W3112873670 hasConcept C502942594 @default.
• W3112873670 hasConcept C51679486 @default.
• W3112873670 hasConcept C53226629 @default.
• W3112873670 hasConcept C54355233 @default.
• W3112873670 hasConcept C552990157 @default.
• W3112873670 hasConcept C86803240 @default.
• W3112873670 hasConceptScore W3112873670C104317684 @default.
• W3112873670 hasConceptScore W3112873670C127848430 @default.
• W3112873670 hasConceptScore W3112873670C151730666 @default.
• W3112873670 hasConceptScore W3112873670C2483381 @default.
• W3112873670 hasConceptScore W3112873670C2778729363 @default.
• W3112873670 hasConceptScore W3112873670C2779282312 @default.
• W3112873670 hasConceptScore W3112873670C2779343474 @default.
• W3112873670 hasConceptScore W3112873670C2779694297 @default.
• W3112873670 hasConceptScore W3112873670C30481170 @default.
• W3112873670 hasConceptScore W3112873670C45091340 @default.
• W3112873670 hasConceptScore W3112873670C501734568 @default.
• W3112873670 hasConceptScore W3112873670C502942594 @default.
• W3112873670 hasConceptScore W3112873670C51679486 @default.
• W3112873670 hasConceptScore W3112873670C53226629 @default.
• W3112873670 hasConceptScore W3112873670C54355233 @default.
• W3112873670 hasConceptScore W3112873670C552990157 @default.
• W3112873670 hasConceptScore W3112873670C86803240 @default.
• W3112873670 hasLocation W31128736701 @default.
• W3112873670 hasOpenAccess W3112873670 @default.
• W3112873670 hasPrimaryLocation W31128736701 @default.
• W3112873670 hasRelatedWork W1991775451 @default.
• W3112873670 hasRelatedWork W2110318292 @default.
• W3112873670 hasRelatedWork W2127738065 @default.
• W3112873670 hasRelatedWork W2150690129 @default.
• W3112873670 hasRelatedWork W2415013360 @default.
• W3112873670 hasRelatedWork W2593558515 @default.
• W3112873670 hasRelatedWork W2800919438 @default.
• W3112873670 hasRelatedWork W2889098804 @default.
• W3112873670 hasRelatedWork W2964895539 @default.
• W3112873670 hasRelatedWork W3030821596 @default.
• W3112873670 hasVolume "20" @default.
• W3112873670 isParatext "false" @default.
• W3112873670 isRetracted "false" @default.
• W3112873670 magId "3112873670" @default.
• W3112873670 workType "article" @default.